Advertisement Fidelity
Home > Boards > US Listed > Biotechs > Compugen (CGEN)

6:01AM Compugen announces results showing its CGEN-15001T drug

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
surf1944 Member Profile
 
Followed By 427
Posts 21,180
Boards Moderated 2
Alias Born 09/11/06
160x600 placeholder
Compugen Says Not Being Investigated in Insider-Trading Probe "Dow Jones News" - 4/7/2014 10:28:32 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 4/7/2014 9:11:39 AM
Compugen Statement Regarding Insider Trading Allegations "Business Wire" - 4/7/2014 9:03:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 3/5/2014 4:11:28 PM
Compugen Ltd. Closes Public Offering of Ordinary Shares "Business Wire" - 3/5/2014 4:05:00 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 2/28/2014 2:49:27 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 2/28/2014 2:47:11 PM
Compugen Ltd. Prices Public Offering of Ordinary Shares "Business Wire" - 2/28/2014 9:15:00 AM
Compugen Ltd. Announces Proposed Public Offering of Ordinary Shares "Business Wire" - 2/27/2014 4:09:00 PM
Compugen to Present Cancer Immunotherapy Programs at Three International Cancer Conferences in March "Business Wire" - 2/20/2014 7:00:00 AM
Annual and Transition Report (foreign Private Issuer) (20-f) "Edgar (US Regulatory)" - 2/18/2014 5:04:30 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 2/14/2014 8:31:33 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 2/11/2014 4:02:28 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 2/11/2014 7:01:51 AM
Compugen Ltd. Reports Fourth Quarter and Calendar 2013 Results "Business Wire" - 2/11/2014 7:00:00 AM
Compugen Fourth Quarter and Yearend 2013 Conference Call Scheduled for Tuesday, February 11, 2014 at 10:00 AM EST "Business Wire" - 2/4/2014 7:00:00 AM
Compugen to Present Predictive Methodology for Discovery of Novel Immune Checkpoints at the Washington BioLeaders Forum "Business Wire" - 1/22/2014 7:00:00 AM
Compugen Announces Addition of Prof. Drew Pardoll to Its Scientific Advisory Board "Business Wire" - 1/21/2014 7:00:00 AM
Compugen to Significantly Expand Immuno-Oncology Activities During 2014 "Business Wire" - 1/7/2014 9:26:00 AM
Compugen Discloses Discovery of Five Potential Cancer Targets for Antibody Drug Conjugate Therapy "Business Wire" - 12/11/2013 7:00:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 10/29/2013 9:26:36 AM
Compugen Ltd. Reports Third Quarter 2013 Financial Results "Business Wire" - 10/29/2013 9:25:00 AM
Compugen Third Quarter 2013 Conference Call Scheduled for Tuesday, October 29, 2013 at 10:00 AM EST "Business Wire" - 10/22/2013 7:00:00 AM
Compugen Presents Experimental Results Supporting Induction of Immune Tolerance by CGEN-15001 Drug Candidate "Business Wire" - 10/16/2013 7:00:00 AM
surf1944   Thursday, 02/02/12 10:57:15 AM
Re: surf1944 post# 109
Post # of 144 
6:01AM Compugen announces results showing its CGEN-15001T drug may have potential for cancer immunotherapy (CGEN) 5.30 : Co announced results demonstrating the therapeutic potential of CGEN-15001T as a drug target for treatment of multiple cancers by means of monoclonal antibody ("mAb") therapy. These results indicate that CGEN-15001T is expressed on numerous types of cancer, such as carcinomas, sarcomas, melanoma and hematological cancers as well as on immune cells. These findings, together with previous results supporting its active immunomodulatory effect, 'strongly support CGEN-15001T's potential as a powerful drug target for treatment of various solid and hematological cancers, an area of great interest to the pharmaceutical industry.'


surf's up......crikey



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist